Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Albuquerque Neuroscience Inc

Neither a doctor nor a teaching hospital

Research payments

$1,636,907

192 payments

Through program year 2025, Albuquerque Neuroscience Inc is reported as receiving $1,636,907 in research payments, across 192 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $11,529 4
2024 Research $174,137 7
2023 Research $85,365 18
2022 Research $186,787 22
2021 Research $290,733 48
2020 Research $608,400 52
2019 Research $279,956 41

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sage Therapeutics, Inc. $1,021,360 68 payments
  2. Abbott Laboratories $386,621 51 payments
  3. Novartis Pharmaceuticals Corporation $80,487 1 payment
  4. Eisai Inc. $47,493 13 payments
  5. Eli Lilly and Company $42,515 20 payments
  6. Allergan Inc. $27,622 8 payments
  7. Teva Pharmaceuticals USA, Inc. $16,650 8 payments
  8. Boehringer Ingelheim International GmbH $5,211 13 payments
  9. ACADIA Pharmaceuticals Inc $4,187 4 payments
  10. Biohaven Pharmaceuticals, Inc. $3,884 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $526,715 43 payments
  2. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $231,684 2 payments
  3. FreeStyle Libre Flash Glucose Monitoring System Post Approval Study $158,491 20 payments
  4. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $150,597 12 payments
  5. FreeStyle Libre Flash Glucose Monitoring System Post Approval Study $117,763 7 payments
  6. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $80,487 1 payment
  7. 217-Mdd-303 $78,014 2 payments
  8. FreeStyle Libre Flash Glucose Monitoring System Post Approval Study For Pediatric Patients $63,900 1 payment
  9. An Open-label, Parallel-Group Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects $47,493 13 payments
  10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $17,256 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record